Highlights

  • EMVision has been awarded a $3 million non-dilutive CRC-P grant to develop its First Responder device for traumatic brain injury.
  • The grant will fund development and preliminary clinical validation for detecting traumatic intracranial haemorrhage.
  • TBI represents a new indication that could more than double the company's consumables addressable opportunity.
  • Clinical study protocol and ethics are targeted for the first half of 2027, with study activation in the second half.

EMVision Medical Devices Limited (ASX:EMV), an Australian medical device company developing portable neurodiagnostic technology, has announced the award of a $3 million grant under Round 19 of the Australian Government's Cooperative Research Centres Projects (CRC-P) program. The grant will fund the development and preliminary clinical validation of EMVision's First Responder brain scanner for the assessment of suspected traumatic brain injury (TBI), with a primary focus on detecting traumatic intracranial haemorrhage (tICH). This is a separate and additional award to the $3 million CRC-P grant the company received in 2025 for its emu Regional Benefits Study in stroke, making this EMVision's third CRC-P award in its history.

The Clinical Challenge of Traumatic Brain Injury

Traumatic brain injury is among the leading causes of death and disability worldwide and arises when an external force injures the brain, whether from a fall, road accident, sporting collision, or blast. The most time-critical complication is bleeding inside the skull, known as intracranial haemorrhage, which can expand rapidly and may require urgent neurosurgical intervention. The challenge for clinicians is that the signs of a bleed can be subtle or delayed, meaning that patients with suspected head injuries are routinely transported to hospital for a CT scan. Research suggests the overwhelming majority of these scans confirm no injury, while patients who genuinely require urgent intervention may face delays in reaching specialist care. The absence of a widely accessible point-of-care diagnostic tool represents a gap that portable scanning technology could address.

Leveraging Stroke Technology for a New Indication

EMVision's First Responder is a portable, non-ionising brain scanner that uses electromagnetic technology to detect changes in the dielectric properties of brain tissue. The company's existing work on stroke has focused on detecting blood from haemorrhagic stroke, and the company believes that fresh blood, whether from a stroke or a traumatic injury, shares the same dielectric properties. This means that the bleed detection algorithms developed for stroke provide a foundation for adapting the technology to TBI. The TBI indication would expand the clinical settings in which the First Responder could be deployed, extending beyond ambulances and emergency departments to include aged care facilities, military settings, and sporting environments, potentially increasing the total addressable per-scan consumable opportunity significantly.

Aged Care, Military, and Sporting Applications

Falls are the most common cause of TBI in older people, and aged care residents fall frequently, often while taking medications that increase the risk of a bleed. Current practice typically involves ambulance transport to an emergency department for a CT scan, the majority of which return negative results. A portable scanner capable of ruling out a bleed at the point of care in an aged care Facility could reduce unnecessary hospital transfers and focus emergency resources on the smaller number of residents who require urgent intervention. In military settings, head and neck trauma has been described as a characteristic injury of recent allied military conflicts, underscoring the Demand for reliable, field-deployable diagnostic tools that can operate without access to hospital imaging infrastructure.

Grant Structure and Clinical Timeline

The CRC-P is a matched funding program, meaning that the $3 million government grant is to be complemented by cash or in-kind contributions from project partners. Project partners include Metro North Hospital and Health Service and Titan Prehospital Innovation. Activities are scheduled to commence in the first quarter of 2027, subject to the execution of a Funding Agreement with the Commonwealth and Partner Agreements with the project participants. Clinical study protocol and ethics activities are planned for the first half of 2027, with study activation targeted for the second half of the year. The study will collect clinical data and paired CT and MRI imaging from suspected TBI patients to train and validate the company's haemorrhage detection algorithms, with preliminary sensitivity and specificity outcomes intended to underpin the pathway to regulatory clearance for the TBI indication.

Key Insights

EMVision Medical Devices has taken a strategically meaningful step by securing government funding to advance a second clinical indication for its First Responder technology. If the TBI development programme succeeds, it would significantly broaden the market addressable by the device, potentially extending beyond hospital and ambulance settings to include aged care, military, and sporting environments. The non-dilutive nature of the CRC-P grant means the company receives financial support for this development work without issuing new equity. The TBI programme runs in parallel with the stroke programme, and both indications share the same underlying device platform. Successful preliminary clinical validation in TBI would be a meaningful milestone in the company's pathway to commercialisation and would add further dimension to its long-term product and market strategy.

Looking ahead, the TBI programme represents a logical and capital-efficient expansion of EMVision's commercial opportunity. By leveraging the same underlying device platform already under development for stroke, the company can pursue a second indication without the cost and time of developing a fundamentally different product. The non-dilutive nature of the CRC-P grant preserves Shareholder Equity while funding a meaningful programme of clinical work. If preliminary clinical data confirms the First Responder's ability to detect traumatic intracranial haemorrhage with clinically useful sensitivity and specificity, the resulting body of evidence would form the basis for the next phase of the regulatory pathway for TBI, running in parallel with the stroke regulatory programme and potentially creating a device with far broader deployment appeal across emergency medical services globally.